INSMED Inc (INSM) earnings date

Nasdaq · Large cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 38 days, typically, give or take 8 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Oct 29, 2026before open 29 8-K
Q2 FY2026Thu, Aug 6, 2026before open 37 8-K
Q1 FY2026Thu, May 7, 2026before open 37 8-K
Q4 FY2025Thu, Feb 19, 2026before open 50 8-K
Q3 FY2025Thu, Oct 30, 2025before open 30 8-K
Q2 FY2025Thu, Aug 7, 2025before open 38 8-K
Q1 FY2025Thu, May 8, 2025before open 38 8-K
Q4 FY2024Thu, Feb 20, 2025before open 51 8-K

What they guided beta

Q3 FY2026 "—Company Raises 2026 BRINSUPRI Revenue Guidance to $1.35 Billion to $1.4 Billion—" exhibit
Q3 FY2026 "—Company Raises 2026 ARIKAYCE Revenue Guidance to $460 Million to $470 Million—" exhibit
Q3 FY2026 "the low end of our full-year 2026 revenue guidance for both products." exhibit
Q3 FY2026 "interstitial lung disease (PH-ILD) and expects to complete enrollment in the first half of 2028." exhibit
Q3 FY2026 "Insmed continues to anticipate initiating a Phase 3 study of TPIP in patients with idiopathic pulmonary fibrosis (IPF) in the first half of 2027." exhibit
Q2 FY2026 "—Company Raises 2026 BRINSUPRI Revenue Guidance to $1.25 Billion to $1.40 Billion—" exhibit
Q2 FY2026 "—Company Reiterates 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million—" exhibit
Q2 FY2026 "Insmed continues to anticipate a regulatory decision for brensocatib for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in Japan in the second half of 2026." exhibit
Q2 FY2026 "Insmed continues to anticipate initiating a Phase 3 study of TPIP in patients with progressive pulmonary fibrosis (PPF) in the second half of 2026 and a Phase 3 study in patients with idiopathic" exhibit
Q2 FY2026 "The Company raised its guidance for full-year 2026 BRINSUPRI revenues to a range of $1.25 billion to $1.40 billion from the previous guidance of at least $1 billion." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/INSM
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/INSM

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

INSM earnings date badge

HTML

<a href="https://veritasdata.dev/company/INSM/"><img src="https://veritasdata.dev/embed/INSM.svg" alt="INSM earnings date" width="240" height="56"></a>

Markdown

[![INSM earnings date](https://veritasdata.dev/embed/INSM.svg)](https://veritasdata.dev/company/INSM/)

Script

<script async src="https://veritasdata.dev/embed/INSM.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/INSM"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.